ESR2 and prostate cancer: Table 1 provides a summary of the castration-resistant prostate cancer study models used to evaluate ERα and ERβ expression. Figure 2 shows how PCa development leads to CRPC progression after ADT, mediated by ERα and ERβ via alternative estrogen signalling pathways.